Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dose Finding, Safety, Pharmacokinetic and Pharmacodynamic Study of the Vascular Targeting Agent Exherin™ (ADH-1) Administered Once Weekly in 3 Week Cycles by Intravenous Infusion in Patients With N-Cadherin Expressing, Incurable, Solid Tumors (Adherex Protocol Number AHX-01-004)

NCT00265057 is registered in ClinicalTrials.gov with Adherex Technologies, Inc. as lead sponsor.

NCT NCT00265057
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00265057 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dose Finding, Safety, Pharmacokinetic and Pharmacodynamic Study of the Vascular Targeting Agent Exherin™ (ADH-1) Administered Once Weekly in 3 Week Cycles by Intravenous Infusion in Patients With N-Cadherin Expressing, Incurable, Solid Tumors (Adherex Protocol Number AHX-01-004)
Lead sponsor
Adherex Technologies, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
June 30, 2005
Completion date
January 31, 2008
Enrollment
Not reported
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms